| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that results from pre-clinical studies of Aeterna's AIM Biologicals for the potential treatment of Parkinson's Disease ("PD") were accepted for presentation at IMMUNOLOGY2022™, the Annual Event of the American Association of Immunologists, to be held May 6-10, 2022 in Portland, Oregon.
The abstract was selected for poster presentation and oral presentation at the congress, which will be given by Prof. Joerg Wischhusen, PhD, Head of the Laboratory of Experimental Tumor Immunology, Department of Obstetrics and Gynecology, School of Medicine, University of Wuerzburg ("the University"). Details of the abstract and presentations are as follows:
Title: α-synuclein peptides presented on chimeric MHC class Ib molecules prevent loss of substantia nigra neurons in an animal model for Parkinson's disease1
Number: P931
Category: Therapeutic Approaches to Autoimmunity
Oral Presentation
| Session Title: | Immune-Based Therapeutics for Neurological Disease |
| Date and time: | Friday, May 6, 2022, at 2:15 – 2:30 PM PT |
| Location: | Room B113-116, Oregon Convention Center (OCC), Portland, Oregon, USA |
Poster Presentation
| Session Title: | Therapeutic Approaches to Autoimmunity and Other Diseases |
| Date and time: | Saturday, May 7, 2022, at 2:30 – 3:45 PM PT |
| Location: | Exhibition Hall, Oregon Convention Center (OCC), Portland, Oregon, USA |
"We are pleased that this abstract was accepted for presentation at IMMUNOLOGY2022, the largest annual immunology event worldwide," commented Dr. Klaus Paulini, Chief Executive Officer of Aeterna Zentaris. "In collaboration with Aeterna, Prof. Wischhusen, Prof. Chi Wang Ip, and their teams at the University are advancing the in-vitro and in-vivo characterization of α-synuclein specific AIM Biologicals to explore the therapeutic potential in PD. We are encouraged by the data being presented from AAV-A53T-α-synuclein Parkinson's disease mice, a new mouse model which replicates human PD with high validity."
Prof. Joerg Wischhusen of the University, added, "My co-inventor Valentin Bruttel and I collaborated with the group of Prof. Ip at the Department of Neurology to show that treatment of PD mice with α-synuclein specific AIM Biologicals prevents the development of mobility impairments. Further, we were pleased to see the induction of antigen-specific regulatory T cells and rescue of dopaminergic neurons in the substantia nigra. We are very much looking forward to exploring the therapeutic potential of AIM Biologicals in this disease together with Aeterna's team."
The abstract is now available through the AAI Events conference app.
